1/34
Looks like no tags are added yet.
Acetylcholine — Neurotransmitter used in the CNS, autonomic nervous system, and neuromuscular junction.
Choline — Precursor used to synthesize acetylcholine.
Acetyl-CoA — Molecule that combines with choline to produce acetylcholine.
Choline acetyltransferase — Enzyme that synthesizes acetylcholine from choline and acetyl-CoA.
ACh synthesis — Choline + acetyl-CoA → acetylcholine, catalyzed by choline acetyltransferase.
ACh storage — Acetylcholine is packaged into synaptic vesicles before release.
ACh release — Acetylcholine is released from synaptic vesicles into the synaptic space.
Acetylcholinesterase — Enzyme that rapidly breaks down acetylcholine and terminates its signal.
AChE inhibition — Prevents rapid breakdown of acetylcholine, increasing and prolonging cholinergic signaling.
Nicotinic receptor — Ionotropic acetylcholine receptor that directly controls an ion channel and produces fast effects.
Muscarinic receptor — Metabotropic acetylcholine receptor that acts through G proteins and second messengers.
Nicotinic versus muscarinic receptors — Nicotinic receptors are ionotropic and fast; muscarinic receptors are metabotropic and slower and modulatory.
Nicotinic receptor desensitization — Prolonged exposure to an agonist can cause nicotinic receptors to enter a desensitized state in which they respond less effectively.
Desensitized nicotinic receptor — Receptor state in which the receptor responds less effectively to an agonist after prolonged exposure.
Resensitization — Return of a desensitized nicotinic receptor to a responsive state.
Muscarinic receptors — Five major types of muscarinic receptors are M1 through M5.
M5 receptor — Muscarinic receptor found in areas including the hippocampus, hypothalamus, and midbrain dopamine regions; may contribute to drug reward and dependence.
Basal forebrain cholinergic system — Acetylcholine system projecting broadly to the cortex and hippocampus and involved in attention, learning, and memory.
ACh and cognition — Acetylcholine contributes to attention, learning, memory, and cortical activation.
Alzheimer's disease and acetylcholine — Loss of cholinergic function contributes to cognitive impairment in Alzheimer's disease.
AChE inhibitors and Alzheimer's — AChE inhibitors increase acetylcholine signaling and can provide limited symptomatic cognitive benefits.
Autonomic ganglia — Primarily use nicotinic acetylcholine receptors.
Parasympathetic targets — Primarily use muscarinic acetylcholine receptors.
Neuromuscular junction — Site where motor neurons communicate with skeletal muscle using nicotinic acetylcholine receptors.
Cholinergic blockade at the neuromuscular junction — Blocking acetylcholine release or receptors at the neuromuscular junction can produce weakness or paralysis.
M3 receptor — Muscarinic receptor involved in glandular secretion and insulin release.
M3 and insulin — Acetylcholine activation of M3 receptors on pancreatic beta cells stimulates insulin secretion.
M3 and salivation and lacrimation — M3 activation contributes to salivation and tear production.
Muscarinic antagonist — Drug that blocks muscarinic receptors and reduces parasympathetic signaling.
Atropine — Muscarinic antagonist that blocks acetylcholine's effects at muscarinic receptors.
Scopolamine — Muscarinic antagonist that blocks muscarinic acetylcholine receptors.
Antimuscarinic effects — Blocking muscarinic signaling can produce effects such as dry mouth by reducing parasympathetic secretion.
Blood-brain barrier and cholinergic drugs — Whether a drug crosses the blood-brain barrier helps determine whether it produces central effects, peripheral effects, or both.
Central acetylcholine — Acetylcholine signaling in the CNS involved in attention, learning, and memory.
Peripheral acetylcholine — Acetylcholine signaling involved in autonomic functions and communication at the neuromuscular junction.